Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Acquires 10,100 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Rating) Director Bvf Partners L. P/Il bought 10,100 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were purchased at an average cost of $14.00 per share, with a total value of $141,400.00. Following the acquisition, the director now directly owns 2,036,860 shares of the company’s stock, valued at approximately $28,516,040. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Kymera Therapeutics stock traded down $0.70 during midday trading on Tuesday, reaching $14.18. The company had a trading volume of 592,319 shares, compared to its average volume of 534,474. Kymera Therapeutics, Inc. has a fifty-two week low of $13.62 and a fifty-two week high of $69.12. The stock has a fifty day moving average price of $31.57 and a 200 day moving average price of $42.98. The firm has a market cap of $733.45 million, a PE ratio of -5.72 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMRGet Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.04). Kymera Therapeutics had a negative net margin of 194.23% and a negative return on equity of 30.40%. The business had revenue of $9.62 million during the quarter, compared to analyst estimates of $18.66 million. During the same period last year, the firm posted ($0.29) earnings per share. Kymera Therapeutics’s quarterly revenue was down 48.6% compared to the same quarter last year. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. bought a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $450,000. Wells Fargo & Company MN increased its holdings in shares of Kymera Therapeutics by 60.9% during the second quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock valued at $69,000 after acquiring an additional 541 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Kymera Therapeutics during the third quarter worth $217,000. Principal Financial Group Inc. grew its holdings in Kymera Therapeutics by 56.0% during the third quarter. Principal Financial Group Inc. now owns 7,210 shares of the company’s stock worth $424,000 after buying an additional 2,589 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in Kymera Therapeutics by 24.2% during the third quarter. BlackRock Inc. now owns 3,040,431 shares of the company’s stock worth $178,595,000 after buying an additional 591,914 shares in the last quarter. 77.73% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently commented on KYMR. Piper Sandler decreased their price target on Kymera Therapeutics from $91.00 to $43.00 and set an “overweight” rating on the stock in a research report on Monday. Wells Fargo & Company began coverage on Kymera Therapeutics in a research report on Thursday, February 10th. They issued an “overweight” rating and a $62.00 target price on the stock. B. Riley decreased their target price on Kymera Therapeutics from $67.00 to $50.00 in a research report on Wednesday, May 4th. JPMorgan Chase & Co. began coverage on Kymera Therapeutics in a research report on Thursday, March 10th. They issued a “neutral” rating and a $44.00 target price on the stock. Finally, Morgan Stanley decreased their target price on Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 2nd. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $64.00.

Kymera Therapeutics Company Profile (Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.